Status:
COMPLETED
Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This trial is conducted in Asia. This trial aims for evaluating the glycaemic control, measured as glycosylated haemoglobin (Hb1Ac), of once daily insulin detemir as an add-on to oral antidiabetic dru...
Eligibility Criteria
Inclusion
- Type 2 diabetes (diagnosed more than 12 months ago)
- HbA1c greater than 7.0 and less than 12.0% at screening
- Currently on any OAD in more than 3 months ago
- BMI (Body Mass Index) less than 35kg/m2
Exclusion
- Previous treatment with insulin in more than 7 days within the last 3 months
- Uncontrolled treated/untreated hypertension (systolic blood pressure greater than 180mmHg and/or diastolic blood pressure less than 110mmHg)
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT00455858
Start Date
November 1 2007
End Date
October 1 2008
Last Update
February 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul, South Korea